001     280290
005     20250907001845.0
024 7 _ |a 10.1007/s00401-025-02919-x
|2 doi
024 7 _ |a pmid:40783910
|2 pmid
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:180224591
|2 altmetric
037 _ _ |a DZNE-2025-00945
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Alidadiani, Sara
|b 0
245 _ _ |a Brain transcriptomics highlight abundant gene expression and splicing alterations in non-neuronal cells in aFTLD-U.
260 _ _ |a Heidelberg
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756894587_1279
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions (aFTLD-U) is a rare cause of frontotemporal lobar degeneration (FTLD), characterized postmortem by neuronal inclusions of the FET family of proteins (FTLD-FET). The recent discovery of TAF15 amyloid filaments in aFTLD-U brains represents a significant step toward improved diagnostic and therapeutic strategies. However, our understanding of the etiology of this FTLD subtype remains limited, which severely hampers translational research efforts. To explore the transcriptomic changes in aFTLD-U, we performed bulk RNA sequencing on the frontal cortex tissue of 21 aFTLD-U patients and 20 control individuals. Cell-type deconvolution revealed loss of excitatory neurons and a higher proportion of astrocytes in aFTLD-U relative to controls. Differential gene expression and co-expression network analysis, adjusted for the shift in cell-type proportions, showed dysregulation of mitochondrial pathways, transcriptional regulators, and upregulation of the Sonic hedgehog (Shh) pathway, including the GLI1 transcription factor, in aFTLD-U. Overall, oligodendrocyte and astrocyte-enriched genes were significantly over-represented among the differentially expressed genes. Differential splicing analysis confirmed the dysregulation of non-neuronal cell types with significant splicing alterations, particularly in oligodendrocyte-enriched genes, including myelin basic protein (MBP), a crucial component of myelin. Immunohistochemistry in frontal cortex brain tissue also showed reduced myelin levels in aFTLD-U patients compared to controls. Together, these findings highlight a central role for glial cells, particularly astrocytes and oligodendrocytes, in the pathogenesis of aFTLD-U, with disruptions in mitochondrial activity, RNA metabolism, Shh signaling, and myelination as possible disease mechanisms. This study offers the first transcriptomic insight into aFTLD-U and presents new avenues for research into FTLD-FET.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Glial cells
|2 Other
650 _ 7 |a Mitochondria
|2 Other
650 _ 7 |a Sonic hedgehog signaling
|2 Other
650 _ 7 |a Splicing
|2 Other
650 _ 7 |a Transcriptomics
|2 Other
650 _ 7 |a aFTLD-U
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Transcriptome
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Frontotemporal Lobar Degeneration: genetics
|2 MeSH
650 _ 2 |a Frontotemporal Lobar Degeneration: pathology
|2 MeSH
650 _ 2 |a Frontotemporal Lobar Degeneration: metabolism
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Neurons: pathology
|2 MeSH
650 _ 2 |a RNA Splicing
|2 MeSH
650 _ 2 |a Astrocytes: metabolism
|2 MeSH
700 1 _ |a Faura, Júlia
|b 1
700 1 _ |a Wynants, Sarah
|b 2
700 1 _ |a Peeters, Nele
|b 3
700 1 _ |a Van den Broeck, Marleen
|b 4
700 1 _ |a De Witte, Linus
|b 5
700 1 _ |a Policarpo, Rafaela
|b 6
700 1 _ |a Cheung, Simon
|b 7
700 1 _ |a Pottier, Cyril
|b 8
700 1 _ |a Ghayal, Nikhil B
|b 9
700 1 _ |a Mol, Merel O
|b 10
700 1 _ |a van Blitterswijk, Marka
|b 11
700 1 _ |a Udine, Evan
|b 12
700 1 _ |a DeJesus-Hernandez, Mariely
|b 13
700 1 _ |a Baker, Matthew
|b 14
700 1 _ |a Finch, NiCole A
|b 15
700 1 _ |a Asmann, Yan W
|b 16
700 1 _ |a van Rooij, Jeroen G J
|b 17
700 1 _ |a Nguyen, Aivi T
|b 18
700 1 _ |a Ross Reichard, R.
|b 19
700 1 _ |a Nana, Alissa L
|b 20
700 1 _ |a Lopez, Oscar L
|b 21
700 1 _ |a Boxer, Adam L
|b 22
700 1 _ |a Rosen, Howard J
|b 23
700 1 _ |a Spina, Salvatore
|b 24
700 1 _ |a Herms, Jochen
|0 P:(DE-2719)2810441
|b 25
|u dzne
700 1 _ |a Josephs, Keith A
|b 26
700 1 _ |a Petersen, Ronald C
|b 27
700 1 _ |a Rissman, Robert A
|b 28
700 1 _ |a Hiniker, Annie
|b 29
700 1 _ |a Ang, Lee-Cyn
|b 30
700 1 _ |a Grinberg, Lea T
|b 31
700 1 _ |a Halliday, Glenda M
|b 32
700 1 _ |a Boeve, Bradley F
|b 33
700 1 _ |a Graff-Radford, Neill R
|b 34
700 1 _ |a Seelaar, Harro
|b 35
700 1 _ |a Neumann, Manuela
|0 P:(DE-2719)2810592
|b 36
|u dzne
700 1 _ |a Kofler, Julia
|b 37
700 1 _ |a White, Charles L
|b 38
700 1 _ |a Seeley, William W
|b 39
700 1 _ |a van Swieten, John C
|b 40
700 1 _ |a Dickson, Dennis W
|b 41
700 1 _ |a Mackenzie, Ian R A
|b 42
700 1 _ |a De Coster, Wouter
|b 43
700 1 _ |a Rademakers, Rosa
|b 44
773 _ _ |a 10.1007/s00401-025-02919-x
|g Vol. 150, no. 1, p. 17
|0 PERI:(DE-600)1458410-4
|n 1
|p 17
|t Acta neuropathologica
|v 150
|y 2025
|x 0001-6322
856 4 _ |u https://pub.dzne.de/record/280290/files/DZNE-2025-00945%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/280290/files/DZNE-2025-00945%20SUP2.xlsx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/280290/files/DZNE-2025-00945.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/280290/files/DZNE-2025-00945.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:280290
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2810441
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 36
|6 P:(DE-2719)2810592
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)1110001
|k AG Herms
|l Translational Brain Research
|x 0
920 1 _ |0 I:(DE-2719)1210003
|k AG Neumann
|l Molecular Neuropathology of Neurodegenerative Diseases
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110001
980 _ _ |a I:(DE-2719)1210003
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21